In these studies, patients with a higher pre-transfusion Hb level, chronic anemia, that were being being treated for cancer, or that were younger carried a higher risk of inappropriate transfusion, as well as treatment taking place in small non-teaching hospitals and the prescribing physicians having lower expertise. The gene discussed is GSTM1; the disease is cancer.